Compare Lucid Group Inc (LCID) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Medpace Holdings Inc — how do they compare? Lucid Group Inc trades at $6.46 (market cap $2.64B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 6.4× Lucid Group Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| LCID | MEDP | |
|---|---|---|
Market Cap | $2.64B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.77 | $620.59 |
52-Week Low | $4.62 | $393.42 |
Enterprise Value | $5.54B | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.47, down 2.12% on the day, reflecting ongoing investor concerns over persistent losses and cash burn. The stock exhibits a bearish technical trend with key support at $6, while fundamentally, the company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by a -249.21% net income margin. Recent news highlights an operational reset aiming for $1.4 billion in cash savings and a delayed midsize EV launch to 2027.
The outlook remains challenging with significant execution risks, though a $10.50 analyst price target suggests potential upside if cost-cutting and new initiatives like robotaxi partnerships succeed. High cash burn and competitive pressures pose substantial risks to near-term stability.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
